Zwacka, Ralf - University of Essex - School of Biological Sciences

个人简介

2005 - 2013 Lecturer, National University of Ireland Galway, National Centre for Biomedical Engineering Science, Ireland 2001 - 2005 Group Leader, Division of Gene Therapy, University of Ulm, Germany 1997 - 2001 Lecturer, University of Edinburgh, Dept. of Oncology 1995 - 1997 Post-doctoral fellow, University of Pennsylvania, Institute for Human Gene Therapy, USA 1990 - 1995 Ph.D., Open University and Forschungszentrum Karlsruhe, Germany 1988 - 1990 B.Sc. in Biochemistry, University of Manchester (UMIST) 1985 - 1988 Undergraduate courses in Biochemistry and Economics, Free University Berlin, Germany

研究领域

Mesenchymal stem cells and cancer therapy Apoptosis pathways and treatment resistance mechansims in cancer Cell death regulation in stem cells Redox-regulated pathways in cancer and stem cells

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Mohr A, Yu R, Zwacka RM. TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill. BMC Cancer. 2015; 15: 494. Yu R, Albarenque SM, Cool RH, Quax WJ, Mohr A, Zwacka RM. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer. Cancer Biol Ther. 2014; 15: 1658-66. Yu R, Deedigan L, Albarenque SM, Mohr A, Zwacka RM. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to enhanced anti-tumor effects. Cell Death Dis. 2013; 4: e503. Büneker CK, Yu R, Deedigan L, Mohr A, Zwacka RM. IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells. Cancer Lett. 2012; 316: 168-77. Albarenque SM, Zwacka RM, Mohr A. Both human and mouse mesenchymal stem cells promote breast cancer metastasis. Stem Cell Research. 2011; 7: 163-71. Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, Humphreys R, Bachem M, Cohen G, Möller P, Zwacka RM, Debatin KM, Fulda S. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clinical Cancer Research. 2010; 16: 5734-49. Mohr A, Albarenque SM, Yu R, Reidy M, Deedigan L, Fulda S, Zwacka RM. Targeting of XIAP combined with systemic Mesenchymal Stem Cell-mediated delivery of sTRAIL inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells. 2010; 28: 2109-20. Büneker C, Mohr A, Zwacka RM. The TRAIL-Receptor-1:TRAIL-Receptor-3 & -4 ratio is a predictor for TRAIL sensitivity of cancer cells. Onc Reports. 2009; 21:1289-95. Murray TV, McMahon JM, Howley BA, Stanley A, Ritter T, Mohr A, Zwacka R, Fearnhead HO. A non-apoptotic role for caspase-9 in muscle differentiation. J Cell Sci. 2008; 121: 3786-93. Mohr A, Lyons M, Deedigan L, Harte T, Shaw G, Howard L, Barry F, O'Brien T, Zwacka R. Mesenchymal Stem Cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med. 2008; 12: 2628-43. Mohr A, Buneker C, Gough R, Zwacka RM. MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release. Oncogene 2008; 27: 763-74. Weiher H, Zwacka RM. Vitamin D3-24-Hydroxylase (CYP24) as a Potential Target for Intervention with Diabetic and Nondiabetic Nephropathy. Clin Lab. 2007; 53: 85-88. Mohr A, Zwacka RM. In situ trapping of initiator caspases reveals intermediate surprises. Cell Biol Int. 2007; 31: 526-30. La Ferla-Bruhl K, Westhoff MA, Karl S, Kasperczyk H, Zwacka RM, Debatin KM, Fulda S. NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition. Oncogene. 2007; 26: 571-82. Braeuer SJ, Buneker C, Mohr A, Zwacka RM. Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res. 2006; 4: 715-28. Behrend L, Mohr A, Dick T, Zwacka RM. MnSOD induces p53-dependent senescence in colorectal cancer cells. Mol Cell Biol. 2005; 25: 7758-69. Mohr A, Zwacka RM, Jarmy G, Büneker C, Schrezenmeier H, Döhner K, Beltinger C, Wiesneth M, Debatin K-M, Stahnke K. Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene 2005; 24: 2421-29. Kasperczyk H, La Ferla-Brühl K, Westhoff MA, Behrend L, Zwacka RM, Debatin K-M, Fulda S. Betulinic acid as new activator of NF-kappaB: Molecular mechanisms and implications for cancer therapy. Oncogene. 2005; 24: 6945-56. Mohr A, Zwacka RM, Debatin KM, Stahnke K. A novel method for the combined flow cytometric analysis of cell cycle and cytochrome c release. Cell Death Differ. 2004; 11:153-4. Mohr A, Henderson G, Dudus L, Herr I, Kuerschner T, Debatin K-M, Weiher H, Fisher K, Zwacka RM. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumour regression. Gene Therapy. 2004; 11:535-45.